“The new investigational estrogen receptor (ER) degrader GDC-0810 was safe and tolerable in postmenopausal women with advanced ER-positive breast cancer, and a subset of the women, all of whom were previously treated with standard endocrine therapy, gained clinical benefit from the drug, according
“The new investigational estrogen receptor (ER) degrader GDC-0810 was safe and tolerable in postmenopausal women with advanced ER-positive breast cancer, and a subset of the women, all of whom were previously treated with standard endocrine therapy, gained clinical benefit from the drug, according
このブックマークにはスターがありません。
最初のスターをつけてみよう！
Investigational ER degrader safe, with early signs of antitumor activity against advanced ER-positive breast cancer
1 人がブックマーク・1 件のコメント
＼ コメントが サクサク読める アプリです ／